CABA
$11.60
Cabaletta Bio
$.34
3.02%
CABA
Earnings Whisper ®
N/A
4th Quarter December 2021
Consensus:  ($0.68)
Revenue:  N/A
Monday
Jan 31
7:05 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when CABA reports earnings?
Beat
Meet
Miss

Where is CABA's stock price going from here?
Up
Flat
Down
Stock chart of CABA
Analysts
Summary of analysts' recommendations for CABA
Score
Grade
Pivots
Resistance
-
-
-

-

Support
-
-
-
Tweet
Growth
Description
Cabaletta Bio Inc. is a clinical stage biotechnology company. It is focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's product pipeline consists of DSG3-CAART, DSG3/1-CAART, MuSK-CAART and FVIII-CAART which are in clinical stage. Cabaletta Bio Inc. is based in Philadelphia, United States.